Degludec: A novel basal insulin

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 1, 2012, Pages 18-23

  Kalra, Sanjay ^a   Baruah, Manash P ^b   Niazi, Asfandyar K ^c  

^a Bharti Hospital and BRIDE ^*  (India)

^b Excel Center   (India)

^c SHIFA COLLEGE OF MEDICINE   (Pakistan)

Author keywords

Analogs; Basal insulin; Degludec; Detemir; Glargine

Indexed keywords

HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN RECEPTOR; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE;

CHEMICAL STRUCTURE; DIABETES MELLITUS; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; LEGISLATION, DRUG; PATENTS AS TOPIC; TREATMENT OUTCOME;

EID: 84856530713     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412799015326     Document Type: Review

References (35)

1. Polonsky KS, Given BD, Van Canter E. Twenty four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81:442-8.
2. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011; 13(1):S5-S14.
3. Kalra S, Unnikrishnan AG, Baruah M, Kalra B. Degludec insulin: A novel basal insulin. Ind J End Met 2011; 15(5): 12-6.
4. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 1999; 354(9190):1604-7.
5. Arnold S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract 2010; 64(10): 1415-24.
6. Meneghini L, Liebl A, Abrahamson MJ. Insulin Detemir: A historical perspective on a modern basal insulin analogue. Prim Care Diabetes 2010;4(1):S31-42.
7. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: An example of applied medical science. Dia Obes Met 2009; 11(1):5-19.
8. Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes Int J Clin Pract 2010; 64(10):1415-24.
9. Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011; 54(9):2254-62
10. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JWW, Haak HR, Geelhoed-Duijvestijn PH. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: Results from a large population-based follow-up study. Diabetologia 2011; [Epub ahead of print].
11. Bolli GB, Owens DR. Insulin glargine. Lancet 2000;356:443-5.
12. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49(12):2142-8.
13. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: A randomized, controlled trial. Diabetes Care 2011; 34(3): 669-74.
14. th Scientific Sessions. Orlando, USA (2010).
15. th Scientific Sessions. Orlando, USA (2010).
16. Jonassen I, Hoeg-Jensen T, Havelund S, Ribel U. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co formulation. J Pept Sci 2010;16:32
17. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK, et al. Insulin degludec: Less pharmacodynamic variability than insulin glargine under steady-state conditions. Diabetologia 2010;53(1):S387
18. Nosek L, Heise T, Bottcher SG, Hastrup H, Haahr H. Ultra-longacting insulin degludec has a flat and stable glucose-lowering effect. American Diabetes Association - 71st Scientific Sessions. San Diego, USA (2011).
19. Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase 2 trial. Lancet 2011; 377:924-31.
20. Garber AJ, King AB, Francisco AM, Endahl L, Hollander PA. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-Year results from a randomized basal-bolus trial in people with type 2 diabetes. American Diabetes Association - 71st Scientific Sessions. San Diego, USA (2011).
21. st Scientific Sessions. San Diego, USA (2011).
22. Heise T, Hovelmann U, Nosek L, Bottcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. American Diabetes Association - 71st Scientific Sessions. San Diego, USA (2011).
23. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, et al. Insulin degludec in type 1 diabetes: Randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34:661-5.
24. Heller S, Francisco AM, Pei H, Russel-Jones D. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-Year results from a randomized basal-bolus trial in type 1 diabetes. American Diabetes Asscoiation - 71st Scientific Sessions. San Diego, USA (2011).
25. st Scientific Sessions. San Diego, USA (2011).
26. Kalra S, Kalra B, Agrawal N, Khare S. Recent patents in oral insulin. Recent Pat Endocr Metab Immune Drug Discov 2010; 4(3): 248-52.
27. Baker, J.C., Hanquier, J.M. Acylated insulin analogs. US5693609 (1997).
28. Pohl, R., Kashyap, N., Hauser, R., Ozhan, K., Steiner, S.S. Insulin with a basal release profile. US20100069292 (2010).
29. Radhakrishnan, B., Aggarwal, D., Ferro, M., James, K.D., Malkar, N.B., Miller, M.A., Puskas, M., Ekwuribe, N.N. Insulin-oligomer conjugates, formulations and uses thereof. US0124553 (2011).
30. Radhakrishnan, B., Aggarwal, D., Ferro, M., James, K.D., Malkar, N.B., Miller, M.A., Puskas, M., Ekwuribe, N.N. Cation complexes of insulin compound conjugates, formulations and uses thereof. US0118179 (2011).
31. Steiner, S.S., Pohl, R. Rapid acting and long acting insulin combination formulations. US7718609 (2010).
32. Kashyap, N., Steiner, S.S., Pohl, R. Insulin formulations for insulin release as a function of tissue glucose levels. US 0175840 (2009).
33. Plum, A., Steensgaard, D.B., Thomsen, J.K., Schlein, M., Markussen, A.S.K., Poulsen, C. Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules. US20110152185 (2011).
34. Lau, J.R., Geho, B. Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal. US7871641 (2011).
35. Buysman E, Conner C, Aagren M, Bouchard J, Liu F. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes. Curr Med Res Opin 2011; 27(9):1709-17.